Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/breakthrough-in-treatment-of-cervical-high-grade-squamous-intraepithelial-lesion-release-of-positive-results-from-multicenter-phase-iii-global-clinical-study-302092249.html
https://www.prnewswire.com/news-releases/photocure-partner-asieris-announces-positive-international-phase-iii-clinical-trial-results-for-cevira-and-data-presentations-at-the-2024-eurogin-congress-and-sgo-annual-meeting-302091288.html
https://www.prnewswire.com/news-releases/asieris-releases-phase-iii-clinical-study-and-real-world-research-data-for-apl-1706-a-bladder-cancer-diagnosis-and-management-drug-at-the-2024-asco-gu-302046514.html
https://www.prnewswire.com/news-releases/asieris-will-present-for-the-first-time-interim-analysis-data-of-oral-apl-1202-in-combination-with-pd-1-inhibitor-tislelizumab-for-neoadjuvant-treatment-of-muscle-invasive-bladder-cancer-at-2024-asco-gu-302044439.html
https://www.prnewswire.com/news-releases/enhancing-leadership-in-gynecology-asieris-pharmaceuticals-appoints-sophia-cao-to-lead-the-newly-established-womens-health-business-unit-accelerating-strategic-expansion-302029233.html
https://www.prnewswire.com/news-releases/apl-2301-a-compound-developed-by-asieris-for-the-treatment-of-acinetobacter-baumannii-infection-was-approved-for-phase-i-clinical-trials-in-australia-302022122.html
https://www.prnewswire.com/news-releases/asieris-unveiled-results-of-its-phase-iii-clinical-study-for-apl-1706-an-imaging-drug-for-diagnosis-or-surgery-of-bladder-cancer-at-the-siu-2023-congress-301954806.html
https://www.prnewswire.com/news-releases/asieris-new-drug-apl-1401-completes-first-administration-in-patient-with-moderately-to-severely-active-uc-301927542.html
https://www.prnewswire.com/news-releases/asieris-obtained-ind-approval-from-nmpa-for-apl-1401-a-drug-for-the-treatment-of-moderately-to-severely-active-ulcerative-colitis-301913403.html
https://www.prnewswire.com/news-releases/asieris-pharmaceuticals-unveils-2023-semi-annual-report-demonstrating-initial-success-of-specialty-pharma-strategy-and-multi-product-synergistic-commercialization-301906832.html